Levosulpiride Aristo (Levosulpiride)

Levosulpiride works by selectively antagonizing dopamine D2 receptors. In the brain this reduces dopaminergic over‑activity that contributes to psychosis, and in the gut it diminishes dopamine‑mediated inhibition of smooth‑muscle activity, thereby enhancing gastric emptying and overall motility.

The appropriate dose of Levosulpiride Aristo is determined by the prescribing clinician based on the specific indication, patient age, renal function, and treatment response. Dosage regimens can vary widely, so patients should follow the exact instructions provided by their healthcare professional.

Safety data for levosulpiride in pregnancy and lactation are limited, and the product is generally not recommended unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To request Levosulpiride Aristo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levosulpiride belongs to the benzamide class and differs from typical antipsychotics by having a more selective D2 antagonism and a notable prokinetic effect. Compared with broader‑spectrum agents, it may present a lower risk of metabolic side effects but still carries the potential for extrapyramidal symptoms and prolactin elevation.

Levosulpiride Aristo should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Maintaining a stable, room‑temperature environment helps preserve the tablet’s potency and prevents degradation.

Levosulpiride Aristo is taken orally, usually with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically advised by a healthcare professional.

Serious risks include neuroleptic malignant syndrome, severe hyperprolactinemia, tardive dyskinesia, seizures, and cardiac arrhythmias such as QT prolongation. Patients should be monitored for early signs of these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Levosulpiride Aristo is contraindicated in individuals with known hypersensitivity to levosulpiride or other benzamide derivatives, and in patients with severe hepatic impairment unless a specialist advises otherwise. Caution is also advised for those with a history of cardiac arrhythmias, uncontrolled epilepsy, or prolactin‑dependent tumors.